An ex vivo experiment using T cells from tumor-draining lymph nodes (LNs) demonstrated that recombinant Sema6D (rSema6D) inhibited T cell activation and proliferation induced by anti-CD3/anti-CD28 stimulation, and this inhibitory effect was partially decreased in Plxna4-KO T cells. Here, PLXNA4 is linked to neoplasm.